Amendia Inc. 02.04.16
Amendia Inc. has launched the OmegaLIF expandable lumbar interbody device, an expandable interbody cage especially designed for use in intervertebral body spinal fusion procedures.
The OmegaLIF was created to provide a solution for skeletally mature patients with degenerative disc disease at one or two contiguous levels from L2-S1, according to the company. The device features a self-locking expansion mechanism that is infinitely adjustable, along with a cannulated bullet nose design for minimal impaction and ease of insertion. The OmegaLIF is streamlined and available in various implant sizes and angulations to fit a variety of patient anatomies and surgical preferences.
“The launch of OmegaLIF is another testament to Amendia’s constant commitment to developing and manufacturing exceptional spinal technology,” said Jeff Smith, CEO of Amendia. “We’re confident that it will positively impact our mission of improving surgical outcomes and bettering the lives of patients with spinal disorders, while simultaneously increasing our product portfolio, allowing us to offer a complete, dynamic medical device line to spine surgeons.”
The OmegaLIF expandable lumbar interbody device is one of several upcoming product launches that Amendia has planned for 2016 – a concerted, year-long effort to increase its participation in designing and manufacturing disruptive spinal technologies for medical devices, paired with leading-edge biologics and instrumentation.
Headquartered in Marietta, Ga., Amendia provides spinal surgical products. The company was founded in 2008.
The OmegaLIF was created to provide a solution for skeletally mature patients with degenerative disc disease at one or two contiguous levels from L2-S1, according to the company. The device features a self-locking expansion mechanism that is infinitely adjustable, along with a cannulated bullet nose design for minimal impaction and ease of insertion. The OmegaLIF is streamlined and available in various implant sizes and angulations to fit a variety of patient anatomies and surgical preferences.
“The launch of OmegaLIF is another testament to Amendia’s constant commitment to developing and manufacturing exceptional spinal technology,” said Jeff Smith, CEO of Amendia. “We’re confident that it will positively impact our mission of improving surgical outcomes and bettering the lives of patients with spinal disorders, while simultaneously increasing our product portfolio, allowing us to offer a complete, dynamic medical device line to spine surgeons.”
The OmegaLIF expandable lumbar interbody device is one of several upcoming product launches that Amendia has planned for 2016 – a concerted, year-long effort to increase its participation in designing and manufacturing disruptive spinal technologies for medical devices, paired with leading-edge biologics and instrumentation.
Headquartered in Marietta, Ga., Amendia provides spinal surgical products. The company was founded in 2008.